Lantheus Medical Imaging, Inc.
Bedford, MA
- UEI
- ZBTPKVDXCKJ7
- CAGE
- 1YCS9
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, Lantheus Holdings, Inc., ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
- Springfield, NJ ZYKDF6W9MBD4
-
- SAM.gov registration date
- Physical address
- 201 Burlington Rd, Bedford, MA 01730, USA
- Website
- lantheus.com
- Founded
- 1956
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $1,873,305 |
| FY2025 | $665,225 |
| FY2024 | $1,065,995 |
| FY2023 | $748,507 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Defense Health Agency | $1,331,997 | |
| 2 | Department of Veterans Affairs | $541,308 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| GE Healthcare | Arlington Heights, IL | 325412 Pharmaceutical Preparation Manufacturing |
| Sun Pharmaceutical Industries, Inc. | Princeton, NJ | 325412 Pharmaceutical Preparation Manufacturing |
| Petnet Solutions, Inc. | Knoxville, TN | 325412 Pharmaceutical Preparation Manufacturing |
| Nphs | Dublin, OH | 325412 Pharmaceutical Preparation Manufacturing |
| Bracco Diagnostics Inc. | Princeton, NJ | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Lantheus Medical Imaging, Inc., a for-profit manufacturer headquartered in Bedford, Massachusetts, supplies diagnostic nuclear medicine imaging agents, radiopharmaceutical products, and medical equipment to the federal healthcare system as a prime contractor across the Veterans Health Administration and Defense Health Agency networks. The company operates exclusively as a prime contractor (100% of awards), competing full-and-open with no set-aside designations across its federal footprint.
Lantheus manufactures and distributes a concrete portfolio of nuclear medicine products: technetium-99m (TechneLite) generators, xenon-133 radiopharmaceuticals, PYLARIFY (piflufolastat F-18) for prostate cancer imaging, injectable diagnostic imaging agents, and contrast media for positron emission tomography and single-photon emission computed tomography procedures. Representative recent work includes a $1.07 million firm fixed-price definitive contract (February 2025) with the Defense Health Agency to supply nuclear medicine pharmaceuticals and TechneLite generators to the Department of Radiology at Dwight D. Eisenhower Army Medical Center under a total small business set-aside; a $541,308 delivery order (July 2026) from Veterans Integrated Service Network 15 for PSMA radiopharmaceutical doses, performed in Bedford, Massachusetts; and a $249,002 BPA call (August 2026) from the Defense Health Agency for PYLARIFY acquisition under the Pharmaceuticals and Drugs GSA Schedule.
Customer concentration is acute. The top customer by potential value, Veterans Integrated Service Network 12, accounts for $229.5 million (79% of total portfolio value) across 49 awards — a dramatic skew compared to the second-ranked Defense Health Agency at $27.6 million across 44 awards. The top five funding agencies cover 94% of combined potential value. By award count, the Navy Bureau of Medicine and Surgery leads with 81 awards ($2.7 million), but this represents volume at much smaller unit values than the VA VISN 12 concentration, signaling a customer-relationship portfolio tilted heavily toward one large VA network.
Lantheus holds two active parent vehicles. A $76 million Federal Supply Schedule contract (Schedule 65-IB, Drugs, Pharmaceuticals & Hematology Related Products) issued by the Veterans Integrated Service Network 12 effective September 30, 2026 through September 30, 2031 serves as the primary vehicle for VA ordering. A $6.5 million single-award Blanket Purchase Agreement with the Defense Health Agency, established July 28, 2023 and extending through July 27, 2028, anchors military treatment facility ordering under the Pharmaceuticals and Drugs GSA Schedule (FSS-61-IB). The broader portfolio includes 2,057 task orders against Federal Supply Schedule V797P5763X ($15.8 million) and 167 task orders against the Pharmaceuticals and Drugs vehicle ($20 million combined potential value), reflecting sustained ordering activity across multiple locations.
Recent activity shows modest award volume: 7 awards in 2026 year-to-date, 4 awards in 2025, 4 in 2024, and 11 in 2023 — consistent with a mature, established vendor managing delivery orders and BPA calls against standing vehicles rather than pursuing new competitive procurements. Only 2 awards ($1.6 million combined potential value) face ultimate completion in the next twenty-four months, presenting minimal near-term recompete exposure for the vendor.
The company's capability concentration aligns with its award footprint: 2,335 of 3,531 awards fall under Pharmaceutical Preparation Manufacturing (NAICS 325412); 881 awards are indexed to Medical and Surgical Instruments, Equipment, and Supplies (PSC code); and 1,223 awards fall under Drugs and Biologicals (PSC). Place of performance is centered at the North Billerica, Massachusetts manufacturing facility with delivery to Defense Health Agency locations (including Bethesda, Maryland) and military treatment facilities nationwide including Tripler Army Medical Center (Hawaii), Brooke Army Medical Center (Texas), Walter Reed National Military Medical Center (Washington, D.C.), and U.S. Naval Hospital Guam. Lantheus also carries a subsidiary, Evergreen Theragnostics, Inc., a for-profit manufacturer, though the source provides no detail on its federal role or capabilities.
Quick answers
Is Lantheus Medical Imaging, Inc. registered in SAM.gov?
Yes. Lantheus Medical Imaging, Inc.'s SAM.gov registration is active through October 21, 2027.
Which contract vehicles does Lantheus Medical Imaging, Inc. hold?
Lantheus Medical Imaging, Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Lantheus Medical Imaging, Inc. received in federal contracts?
Federal contracts obligated $665,225 to Lantheus Medical Imaging, Inc. in fiscal year 2025 and $4,353,032 in fiscal years 2023 through 2027.
How does Lantheus Medical Imaging, Inc. rank among federal contractors?
Lantheus Medical Imaging, Inc.'s parent company, Lantheus Holdings, Inc., ranked #14 in NAICS 325412, #16 in PSC 6505 and #18 in NAICS 3254 in FY2025.
What is Lantheus Medical Imaging, Inc.'s most recent federal award?
Lantheus Medical Imaging, Inc.'s most recent federal contract award is Definity ultrasound contrast agents at brooke army medical center, JBSA fort SAM houston, texas (W81K0026FA137), from Medical Command (Army), on October 1, 2026.
On GovTribe
See Lantheus Medical Imaging, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors